Alnylam Pharmaceuticals
ALNY
523 hedge funds and large institutions have $29.1B invested in Alnylam Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 88 funds opening new positions, 194 increasing their positions, 167 reducing their positions, and 57 closing their positions.
70% more capital invested
Capital invested by funds: $17.2B → $29.1B (+$12B)
54% more first-time investments, than exits
New positions opened: 88 | Existing positions closed: 57
17% more call options, than puts
Call options by funds: $703M | Put options by funds: $600M
16% more repeat investments, than reductions
Existing positions increased: 194 | Existing positions reduced: 167
5% more funds holding
Funds holding: 499 → 523 (+24)
3.63% more ownership
Funds ownership: 91.15% → 94.78% (+3.6%)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$347M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$344M |
| 3 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
+$114M |
| 4 |
BlackRock
New York
|
+$82.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$81.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$158M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$93.3M |
| 3 |
Squarepoint
New York
|
-$76M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$52.5M |
| 5 |
VPC
Vestal Point Capital
New York
|
-$52.3M |
ALNY Hedge Fund Activity: Q2 2024 in Review
523 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2024, worth a combined $29.1B — up 70% from $17.2B a quarter earlier.
Buyers outnumbered sellers: 88 funds opened new ALNY positions and 57 closed out — a net gain of 31 holders — while 194 added to existing stakes and 167 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $347M. The largest seller was Wellington Management Group, cutting an estimated $158M.
- 523 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2024, up from 499 in Q1 2024.
- Funds reported $29.1B of Alnylam Pharmaceuticals stock for Q2 2024, up 70% quarter-over-quarter.
- 88 funds opened new Alnylam Pharmaceuticals positions in Q2 2024 and 57 closed out, a net change of +31 holders.
- The largest Alnylam Pharmaceuticals buyer in Q2 2024 was Fidelity Investments, an estimated $347M added.
- The largest Alnylam Pharmaceuticals seller in Q2 2024 was Wellington Management Group, an estimated $158M sold.
Based on aggregated 13F filings for Q2 2024.